Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (G7)
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved for it are considerable, driven by premium pricing and the likelihood of polypharmacy. Although the market has become congested, commercial interest in PH remains high owing to the need for more-efficacious and disease-modifying agents, as well as the lack of approved treatments for unserved populations.
Questions answered
- What do interviewed thought leaders say about the advantages and disadvantages of novel agents such as Merck & Co.’s sotatercept (Winrevair), United Therapeutics’ ralinepag, and Gossamer Bio’s seralutinib, which are in late-phase development for PH? How will the launch of these agents affect prescribing decisions?
- Generic formulations of several key branded therapies are available. How have these launches impacted prescribing patterns? What effect has generic launches had on entrenched brands, and how will they impact the performance of emerging therapies?
- What are the key unmet needs in PH treatment? How likely are these unmet needs to be fulfilled during the forecast period?
- Pulmonary arterial hypertension patients are typically prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the prescribing considerations dictating physician preferences for later-line treatments, and how do they vary by country / region?
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading cardiologists and pulmonologists; supported by survey data collected for this and other Clarivate research
Epidemiology: Prevalence of PH by country, with population-specific diagnosed and drug-treatment rates
Forecast: 10-year, annualized, drug-level sales and patient share of key PH therapies through 2033, segmented by brands / generics
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Key takeaways
- Market drivers and constraints
- Drug class-specific trends
- Market Forecast Assumptions: pulmonary arterial hypertension
- Market Forecast Dashboard: pulmonary arterial hypertension
- Market Forecast Assumptions: inoperable chronic thromboembolic pulmonary hypertension
- Market Forecast Dashboard: inoperable chronic thromboembolic pulmonary hypertension
- Market Forecast Assumptions: pulmonary hypertension due to interstitial lung disease
- Market Forecast Dashboard: pulmonary hypertension due to interstitial lung disease
- Disease Context
- Epidemiology
- Key updates
- Key takeaways
- Diagnosed prevalent cases of pulmonary hypertension (all causes)
- Diagnosed prevalent cases of pulmonary arterial hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to left heart disease
- Diagnosed prevalent cases of pulmonary hypertension due to lung disease and/or hypoxia
- Diagnosed prevalent cases of chronic thromboembolic pulmonary hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to inoperable chronic thrombotic and/or embolic pulmonary hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to miscellaneous causes
- Diagnosed prevalent cases of pulmonary arterial hypertension by NYHA functional class
- Diagnosed prevalent cases of pulmonary hypertension due to left heart disease by subgroup
- Diagnosed prevalent cases of pulmonary hypertension due to lung disease by subgroup
- Diagnosed and drug-treated population
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Appendix
- Executive Summary
